Study Evaluating Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years And Older With Moderate to Severe Atopic Dermatitis

NCT03575871 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

391

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis, Atopic

Interventions

DRUG: PF-04965842 100 mg
DRUG: PF-04965842 200 mg
DRUG: Placebo

Sponsor

Pfizer